Loyzide M 40mg/500mg Tablet is a combination oral antidiabetic medication containing Gliclazide 40mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. The synergistic action of these agents helps achieve better blood glucose regulation in patients inadequately controlled by diet and exercise alone. Loyzide M is typically prescribed when monotherapy with either agent is insufficient. It is important to initiate therapy with caution, considering patient-specific factors such as renal function, hepatic status, and risk of hypoglycemia. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis associated with Metformin. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver enzymes is recommended during treatment. Patients should be advised to adhere to dietary and lifestyle modifications alongside medication use. Loyzide M 40mg/500mg Tablet should be used under medical supervision, with dose adjustments tailored to individual therapeutic response and tolerability.